JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
JW (Cayman) Therapeutics Co. Ltd has shared promising preliminary data on their innovative relma-cel treatment for Systemic Lupus Erythematosus (SLE) at the EULAR 2024 Congress. Early results indicate significant improvements in SLE patients, with a manageable safety profile and no requirement for steroids or immunosuppressants after treatment. These findings could potentially revolutionize treatment for SLE sufferers and pave the way for further clinical development in autoimmune diseases.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.
